Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Neoleukin Therapeutics

NASDAQ NLTX
$0.0000 -3.49 -%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 21 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

-
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-36.37M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.03
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
11.10M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-

Upcoming events Neoleukin Therapeutics

All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Neoleukin Therapeutics

Stock analysis Neoleukin Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
- 25.03
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
- 3.57
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
1.01 9.56
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
1.01 -0.17
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-52.31 7.67

Price change Neoleukin Therapeutics per year

5.95$ 17.95$
Min Max

Summary analysis Neoleukin Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Neoleukin Therapeutics

Revenue and net income Neoleukin Therapeutics

All parameters

Stock news Neoleukin Therapeutics

All news
18 July 2023 в 14:15

Neoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTX

18 July 2023 в 14:15

Neoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTX

9 March 2023 в 21:05

Neoleukin Therapeutics Shares Climb 29% on 70% Workforce Reduction, Strategic Alternatives

9 March 2023 в 21:01

Neoleukin Therapeutics Shares Climb 29% on 70% Workforce Reduction, Strategic Alternatives

9 March 2023 в 03:05

Stocks to Watch: Avenue Therapeutics, MongoDB, Silvergate Capital, Neoleukin Therapeutics

9 March 2023 в 03:05

Stocks to Watch: Avenue Therapeutics, MongoDB, Silvergate Capital, Neoleukin Therapeutics

9 March 2023 в 01:30

Neoleukin Therapeutics Eyes Strategic Alternatives, Will Cut Staff

9 March 2023 в 01:30

Neoleukin Therapeutics Eyes Strategic Alternatives, Will Cut Staff

15 November 2022 в 14:50

Neoleukin Therapeutics downgraded to hold from buy at Stifel Nicolaus

About company Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Address:
1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Company name: Neoleukin Therapeutics
Issuer ticker: NLTX
ISIN: US64049K1043
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2014-03-07
Sector: Healthcare
Industry: Biotechnology
Site: https://www.neoleukin.com

On which stock exchange are Neoleukin Therapeutics (NLTX) stocks traded?

Neoleukin Therapeutics (NLTX) stocks are traded on NASDAQ.

What is the ticker of Neoleukin Therapeutics stocks (NLTX)?

The stock ticker of Neoleukin Therapeutics’s stocks or in other words, the code is NLTX. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Neoleukin Therapeutics (NLTX) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Neoleukin Therapeutics (NLTX) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Neoleukin Therapeutics (NLTX) stocks traded?

Neoleukin Therapeutics (NLTX) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Neoleukin Therapeutics (NLTX) stocks today?

The current price of Neoleukin Therapeutics stocks on 05.05.2024 is 0 dollars. per share.

What is the dynamics of Neoleukin Therapeutics (NLTX) stocks from the beginning of the year?

Neoleukin Therapeutics (NLTX) quotes have increased by 0% from the beginning of the year up to 0 dollars. per 1 stocks.

How much did Neoleukin Therapeutics (NLTX) stocks increase in мае 2024?

This month Neoleukin Therapeutics (NLTX) quotes have increased by 0% to 0 dollars. per share.

How much are Neoleukin Therapeutics (NLTX) stocks worth?

Today, on October, 05.05.2024 Neoleukin Therapeutics’s (NLTX) stocks cost 0 dollars..

What is the market capitalization of Neoleukin Therapeutics (NLTX)?

Capitalization is the market value of Neoleukin Therapeutics (NLTX) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 05.05.2024, the market capitalization of Neoleukin Therapeutics (NLTX) is estimated at about 0 dollars.